Buprenorphine and related orvinols

Research output: Chapter in Book/Report/Conference proceedingChapter

12 Citations (Scopus)

Abstract

The orvinols, including buprenorphine, emerged from research carried out by Reckitt and Colman in the 1960s and 1970s. Regulatory approval of buprenorphine for the treatment of opioid addiction has been a major success and has ultimately led, in part, to its analgesic activity now being fully exploited. As buprenorphine’s unique clinical profile is documented, efforts continue to rationalise this activity through understanding of its receptor pharmacology. This has included the development of new orvinols with mixed mu and kappa opioid receptor agonist activity and others with efficacy at mu and NOP receptors, the latter of particular interest for the development of new analgesics. Orvinols with mu and kappa antagonist activity, coupled with NOP receptor partial agonism have also been developed and have potential for the treatment of polydrug abuse.
Original languageEnglish
Title of host publicationResearch and Development of Opioid-Related Ligands
EditorsMei-Chuan Ko, Stephen M Husbands
Place of PublicationWashington, DC
PublisherAmerican Chemical Society
Pages127-144
ISBN (Electronic)9780841227835
ISBN (Print)9780841227828
DOIs
Publication statusPublished - 2013

Publication series

NameACS Symposium Series
PublisherAmerican Chemical Society
Volume1131

Fingerprint

Buprenorphine
mu Opioid Receptor
Analgesics
kappa Opioid Receptor
Opioid Analgesics
Pharmacology
Research

Cite this

Husbands, S. M. (2013). Buprenorphine and related orvinols. In M-C. Ko, & S. M. Husbands (Eds.), Research and Development of Opioid-Related Ligands (pp. 127-144). (ACS Symposium Series; Vol. 1131). Washington, DC: American Chemical Society. https://doi.org/10.1021/bk-2013-1131.ch007

Buprenorphine and related orvinols. / Husbands, Stephen M.

Research and Development of Opioid-Related Ligands. ed. / Mei-Chuan Ko; Stephen M Husbands. Washington, DC : American Chemical Society, 2013. p. 127-144 (ACS Symposium Series; Vol. 1131).

Research output: Chapter in Book/Report/Conference proceedingChapter

Husbands, SM 2013, Buprenorphine and related orvinols. in M-C Ko & SM Husbands (eds), Research and Development of Opioid-Related Ligands. ACS Symposium Series, vol. 1131, American Chemical Society, Washington, DC, pp. 127-144. https://doi.org/10.1021/bk-2013-1131.ch007
Husbands SM. Buprenorphine and related orvinols. In Ko M-C, Husbands SM, editors, Research and Development of Opioid-Related Ligands. Washington, DC: American Chemical Society. 2013. p. 127-144. (ACS Symposium Series). https://doi.org/10.1021/bk-2013-1131.ch007
Husbands, Stephen M. / Buprenorphine and related orvinols. Research and Development of Opioid-Related Ligands. editor / Mei-Chuan Ko ; Stephen M Husbands. Washington, DC : American Chemical Society, 2013. pp. 127-144 (ACS Symposium Series).
@inbook{02d56b5307734150bffec2cf3c78fabd,
title = "Buprenorphine and related orvinols",
abstract = "The orvinols, including buprenorphine, emerged from research carried out by Reckitt and Colman in the 1960s and 1970s. Regulatory approval of buprenorphine for the treatment of opioid addiction has been a major success and has ultimately led, in part, to its analgesic activity now being fully exploited. As buprenorphine’s unique clinical profile is documented, efforts continue to rationalise this activity through understanding of its receptor pharmacology. This has included the development of new orvinols with mixed mu and kappa opioid receptor agonist activity and others with efficacy at mu and NOP receptors, the latter of particular interest for the development of new analgesics. Orvinols with mu and kappa antagonist activity, coupled with NOP receptor partial agonism have also been developed and have potential for the treatment of polydrug abuse.",
author = "Husbands, {Stephen M}",
year = "2013",
doi = "10.1021/bk-2013-1131.ch007",
language = "English",
isbn = "9780841227828",
series = "ACS Symposium Series",
publisher = "American Chemical Society",
pages = "127--144",
editor = "Mei-Chuan Ko and Husbands, {Stephen M}",
booktitle = "Research and Development of Opioid-Related Ligands",
address = "USA United States",

}

TY - CHAP

T1 - Buprenorphine and related orvinols

AU - Husbands, Stephen M

PY - 2013

Y1 - 2013

N2 - The orvinols, including buprenorphine, emerged from research carried out by Reckitt and Colman in the 1960s and 1970s. Regulatory approval of buprenorphine for the treatment of opioid addiction has been a major success and has ultimately led, in part, to its analgesic activity now being fully exploited. As buprenorphine’s unique clinical profile is documented, efforts continue to rationalise this activity through understanding of its receptor pharmacology. This has included the development of new orvinols with mixed mu and kappa opioid receptor agonist activity and others with efficacy at mu and NOP receptors, the latter of particular interest for the development of new analgesics. Orvinols with mu and kappa antagonist activity, coupled with NOP receptor partial agonism have also been developed and have potential for the treatment of polydrug abuse.

AB - The orvinols, including buprenorphine, emerged from research carried out by Reckitt and Colman in the 1960s and 1970s. Regulatory approval of buprenorphine for the treatment of opioid addiction has been a major success and has ultimately led, in part, to its analgesic activity now being fully exploited. As buprenorphine’s unique clinical profile is documented, efforts continue to rationalise this activity through understanding of its receptor pharmacology. This has included the development of new orvinols with mixed mu and kappa opioid receptor agonist activity and others with efficacy at mu and NOP receptors, the latter of particular interest for the development of new analgesics. Orvinols with mu and kappa antagonist activity, coupled with NOP receptor partial agonism have also been developed and have potential for the treatment of polydrug abuse.

UR - http://dx.doi.org/10.1021/bk-2013-1131.ch007

U2 - 10.1021/bk-2013-1131.ch007

DO - 10.1021/bk-2013-1131.ch007

M3 - Chapter

SN - 9780841227828

T3 - ACS Symposium Series

SP - 127

EP - 144

BT - Research and Development of Opioid-Related Ligands

A2 - Ko, Mei-Chuan

A2 - Husbands, Stephen M

PB - American Chemical Society

CY - Washington, DC

ER -